About This Fund
Ascenta Capital Fund I is the inaugural $325 million venture capital vehicle raised by Ascenta Capital, a Boston-based biotech investment firm co-founded in 2023 by Evan Rachlin, MD, and Lorence Kim, MD—both former senior executives at Moderna. The fund was established to back development-stage biotechnology companies with differentiated multi-medicine platforms, targeting transformative therapies at the frontier of human medicine. The founding team collectively brings deep expertise from over 30 approved medicines across oncology, rare disease, immunology, and infectious disease. Ascenta Capital Fund I achieved its final close of $325 million in October 2025, having attracted capital from leading institutional investors drawn to the founders' operator background and clinical-stage differentiation thesis.
The fund's investment strategy concentrates on early human trials—typically Series A and crossover rounds—in biotech companies that possess broad, multi-medicine pipelines rather than single-asset bets. Target companies must demonstrate a platform capable of generating multiple therapeutic programs across related disease areas, allowing Ascenta to compound value through portfolio adjacencies. Geographic focus is primarily the United States, where the biotech innovation ecosystem provides the deepest pipeline of pre-clinical and early-clinical candidates. The eight-person investment team applies both clinical development judgment and capital market expertise to portfolio construction, emphasizing drug discovery quality and regulatory path clarity as primary diligence filters.
Early portfolio investments include Angitia Biopharmaceuticals, TRIANA Biomedicines, and Iambic Therapeutics, all reflecting the fund's thesis around platform-driven drug discovery. Ascenta Capital Fund I is supported by a broader 14-person team that includes three executive advisors, lending additional therapeutic-area depth for each investment thesis. The fund operates out of Ascenta Capital's primary office and represents the first chapter of what the founders envision as a series of vehicles dedicated to backing the next generation of multi-medicine biotechnology companies.